



Global News and Announcements

Overview

A huge thank you to all our NCIs who have helped and provided solid support throughout Cohort 2—much appreciated. As we are approaching our 10,000 target—we are gearing up for exciting new ventures in the near future. We are also currently looking into the feasibility of a meeting in Mexico City for our Latin American sites, possibly later in the year.



Recruitment

Cohort 2 recruitment is progressing very well and ahead of our projections—all thanks to you. To date, we have recruited 8,878 patients. We have recruited 89% of our target and we kindly please ask you to continue to encourage the investigational sites in your country so as to not slow down in this summer period because it is a crucial period in recruitment

Thank you....

June has been a busy month with lots of logistics being worked on, future plans discussed, in addition to processing the June site payments. We appreciated your help in encouraging the sites in your respective country to complete the data cleaning in time for this milestone.

Overall Study Status at a Glance


- No. of patients recruited : 8878
- No. of sites selected (actual/planned): 477/490
- No. of sites initiated: 425
- No. of recruiting sites: 391

TRI is also working on another important piece of research , please click below :

FIND OUT ABOUT THE SURVEY NOW

Frontline2 is a global survey, funded by an unrestricted grant from Bayer Pharma AG. The survey will collate the views of oncologists, haematologists, surgeons, radiation oncologists and members of the palliative care team who are responsible for treating cancer-associated thrombosis.

Country Highlights



Sites selected	15
EC submissions completed	14
EC/Regulatory approvals in place	14
Clinical Trial Agreements fully executed	14
Site Initiation Visits completed	14
Patients enrolled	490

Project Team at TRI

Gloria Kayani (Chief Operating Officer), Elizabeth Demmisse (Regional Project Manager), Saba Salman (Regional Project Manager), Luz Angela Gomez (Clinical Trial Administrator).



Site Regulatory Start-up

PI Name	Site #	SIV	Projection during IMVs	Expected Enrolment to date	Actual Enrolment per EDC
Abd Elhamid Ebrahim Mahmoud Salem, Ayman	EGY0405	21-Oct-15	35	26	39
Ahmed Adel Abdel-Azim, Tarek	EGY0406	9-Oct-15	130	96	116
Ayman Fakhry Nagib, Mohamed	EGY0408	23-Nov-15	20	14	20
El- Dessoki, Mohamed	EGY0409	18-Mar-16	20	11	0
Fawzy Abdel Malek, Wagih	EGY0410	4-Dec-15	10	7	15
Gad, Amr	EGY0411	25-Oct-15	13	9	41
Mohamed Essameldin, Sherif	EGY0412	9-Oct-15	20	15	11
Mohamed Sholkamy, Sherif	EGY0413	18-Sep-15	30	23	25
Mohamed, Ahmed	EGY0414	16-Oct-15	30	22	37
Salah ElDin, Hesham	EGY0415	4-Nov-15	8	6	8
Shawky Ahmed, Mostafa	EGY0416	16-Oct-15	10	7	4
Soliman, Mosaad	EGY0417	19-Nov-15	150	106	129
Soliman Abd el Bary, Mostafa	EGY0418	18-Nov-15	30	21	28
Zidan, Hesham	EGY0419	9-Oct-15	20	15	15

To find out more about Frontline2 please click below :



Frontline2
FUNDAMENTAL RESEARCH IN ONCOLOGY AND THROMBOSIS

FIND OUT ABOUT THE SURVEY NOW

Frontline2 is a global survey, funded by an unrestricted grant from Bayer Pharma AG. The survey will collate the views of oncologists, haematologists, surgeons, radiation oncologists and members of the palliative care team who are responsible for treating cancer-associated thrombosis.

frontline2.tri-london.ac.uk

TRI Thrombosis Research Institute

The aim of this research is to describe the evolution of clinical understanding in the field of cancer associated thrombosis since the first FRONTLINE study in 2001, and to highlight variations in care, nationally and internationally.

